In addition, moderate binding affinity between the drug and albumin was reported to be essential for the use of albumin as a tumor targeting carrier that targets tumors based on the enhanced permeability and retention (EPR) effect followed by release of the drug from albumin and uptake inside tumor cells 22–24. The gene discussed is ALB; the disease is neoplasm.